To compare the impact on survival of neo-adjuvant TAI for patients with beyond Milan criteria BCLC stage A/B HCC who underwent hepatectomy.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
344
transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
SUN YAT-SEN University Cancer Center
Guangzhou, Guangdong, China
RECRUITINGOS
overall survival
Time frame: From date of randomization until the date of death from any cause, assessed up to 60 months
RFS
recurrence-free survival
Time frame: From date of randomization until the date of recurrence, assessed up to 60 months
recurrence rate
recurrence rate
Time frame: 1 year, 2 year, 3 year, 5 year after surgery
PFS
progression free survival
Time frame: From date of randomization until the date of progression, assessed up to 60 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.